Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)
- Sponsor
- Northern Jiangsu People's Hospital
- Study ID
- NCT07588334
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cirrhosis, Liver
- Lipid Profiles
- Portal Hypertension
- Splenectomy; Status
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Study Details
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.
Key Dates
- First listed
- May 14, 2026
- Start date
- May 1, 2026
- Status verified
- May 2026
- Primary completion
- Feb 28, 2029
- Completion
- Feb 28, 2029
Study Design
- Enrollment
- 30 participants (estimated)
Primary Outcome Measure
Total cholesterol (TC) level [ Time Frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24 ]
Central Contacts
- Guo-Qing Jiang, MD+8651487373272
- Dou-Sheng Bai, MD+8651487373372
Related Studies
- Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in CirrhosisRecruiting · The Cleveland Clinic · Cleveland, Ohio
- Erlotinib for Hepatocellular Carcinoma ChemopreventionPHASE2 · Not Yet Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in CirrhosisPHASE4 · Recruiting · Mercy Medical Center · Baltimore, Maryland
- Danazol for Treatment of Cytopenias in Patients With CirrhosisPHASE2 · Recruiting · University of Southern California · Los Angeles, California